Clinical trial
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
NCT00369512 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00369512 |
|---|---|
| Title | A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma |
| Official title | A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas |
| Acronym | RAD0503 |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Genentech, Inc. Industry OSI Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 15 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Aug 29, 2006 |
| Last update posted | May 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: